Efficacy and Safety of Low-Dose Dutasteride for Male Androgenic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Trial
January 2025
in “
Annals of Dermatology
”
Studysummary In this study, 0.2 mg dutasteride significantly improved hair growth in men with androgenetic alopecia compared to placebo over 24 weeks, showing similar efficacy to the higher 0.5 mg dose with a favorable safety profile.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on anndermatol.org →